Frost & Sullivan: New Approaches for Chinese Biotechs to Go Global from the Perspective of Hengrui Medicine

As a representative of large Chinese pharmaceutical companies, Hengrui Medicine's successful issuance of H shares this time fully demonstrates the global capital market's recognition of the innovative R&D capabilities of Chinese pharmaceutical companies. What Chinese pharmaceutical companies can solve is not only domestic unmet clinical needs; we also hope that products with high clinical benefits can benefit patients worldwide. Hengrui's appearance on the international stage will also fully boost the confidence of Chinese innovative pharmaceutical companies in listing in Hong Kong, and we believe that more Chinese innovative pharmaceutical companies will tell their own investment stories based on disruptive clinical data and pipelines with high revenue potential.

As of now, Hengrui Medicine already has more than 90 new molecular entities and has also created myths in terms of quantity and amount in overseas BD transactions. The funds raised through this Hong Kong stock offering will be applied to the advancement of clinical R&D and the construction of an innovation platform, providing financial support for creating more first-in-class and best-in-class products, and enabling Chinese innovative drugs to truly go global and benefit patients worldwide. The R&D of innovative drugs cannot be separated from the support of all links in the industry chain. For upstream and downstream enterprises, the internationalization of innovative drugs also means that raw materials, equipment instruments, and service providers related to new drug R&D will gradually align with international standards, creating opportunities for gaining recognition from pharmaceutical companies worldwide.